natgillin/translations-raw huggingface dataset:
authorising and refusing to authorise certain health claims made on foods and referring to the reduction of disease risk
Pärast seda, kui European Natural Soyfood Manufacturers Association (ENSA), European Vegetable Protein Federation (EUVEPRO) ja Soya Protein Association (SPA) olid esitanud määruse (EÜ) nr 1924/2006 artikli 14 lõike 1 punkti a kohase taotluse, pidi toiduohutusamet esitama arvamuse tervisealase väite kohta seoses eraldatud sojavalgu mõjuga ja vere LDL-kolesterooli taseme alanemisega (küsimus nr EFSA-Q-2011-00784) [6].
(Text with EEA relevance)
„On tõendatud, et sojaoa valgurikas komponent alandab vere kolesteroolitaset, mis võib omakorda vähendada südamehaiguste, sealhulgas südame koronaartõve riski.”
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 17(3) thereof,
Esitatud andmete alusel jõudis toiduohutusamet 2. veebruaril 2012 komisjonile ja liikmesriikidele saadetud arvamuses järeldusele, et taotleja määratlusele vastava eraldatud sojavalgu tarbimise ja väidetava mõju vahel ei saa tuvastada põhjuslikku seost.
Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
Pärast seda, kui Health Concern B.V. oli esitanud määruse (EÜ) nr 1924/2006 artikli 14 lõike 1 punkti a kohase taotluse, pidi toiduohutusamet esitama arvamuse tervisealase väite kohta seoses taimsete steroolide ja toote Cholesternorm®mix kombinatsiooniga ning vere LDL-kolesterooli taseme alanemisega (küsimused nr EFSA-Q-2009-00237 ja EFSA-Q-2011-01114) [7].
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State.
„Alandab aktiivselt kolesteroolitaset.”
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’.
Esitatud andmete alusel jõudis toiduohutusamet 17. juulil 2012 komisjonile ja liikmesriikidele saadetud arvamuses järeldusele, et taimsete steroolide ja toote Cholesternorm®mix kombinatsiooni tarbimise ja väidetava mõju vahel ei saa taotletud kasutustingimuste puhul tuvastada põhjuslikku seost.
Following receipt of an application the Authority is to inform without delay the other Member States and the Commission thereof, and to deliver an opinion on the health claim concerned.
Kuna kõnealune väide ei vasta määruses (EÜ) nr 1924/2006 sätestatud nõuetele, ei tohiks lubada seda esitada.
The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.
Pärast seda, kui Minami Nutrition Health BVBA oli esitanud määruse (EÜ) nr 1924/2006 artikli 14 lõike 1 punkti a kohase taotluse, pidi toiduohutusamet esitama arvamuse tervisealase väite kohta seoses eikosapentaeenhappe mõjuga ning arahhidoonhappe ja eikosapentaeenhappe suhtarvu vähenemisega tähelepanupuudulikkuse ja hüperaktiivsuse sündroomiga laste veres (küsimus nr EFSA-Q-2012-00573) [8].
Following an application from Abtei Pharma Vertriebs GmbH, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Calcium and vitamin D3 chewing tablets and bone loss (Question No EFSA-Q-2008-721) [2].
Taotleja esitatud väide oli sõnastatud järgmiselt:
The claim proposed by the applicant was worded as follows:
„On tõendatud, et eikosapentaeenhape vähendab arahhidoonhappe ja eikosapentaeenhappe suhtarvu veres.
‘Chewing tablets with calcium and vitamin D improve bone density in women 50 years and older.
Suur arahhidoonhappe ja eikosapentaeenhappe suhtarv on tähelepanuraskuste tekkimise riskitegur tähelepanupuudulikkuse ja hüperaktiivsuse sündroomi meenutavate sümptomitega lastel.
Thus chewing tablets may reduce the risk of osteoporotic fractures’.
Sellistele lastele on iseloomulik ka väiksem hüperaktiivsus ja/või samaaegselt esinev tõrksus käitumises.”
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 7 August 2009 that a cause and effect relationship had been established between the intake of calcium, either alone or in combination with vitamin D, and reducing the loss of bone mineral density (BMD) in postmenopausal women.
Esitatud andmete alusel jõudis toiduohutusamet 8. aprillil 2013 komisjonile ja liikmesriikidele saadetud arvamuses järeldusele, et kõnealuse väite sihtrühm on haiged (st tähelepanupuudulikkuse ja hüperaktiivsuse sündroomiga lapsed) ja et väidetav mõju on seotud haiguse raviga.
Reducing the loss of BMD may contribute to a reduction in the risk of bone fractures.
Määrusega (EÜ) nr 1924/2006 täiendatakse Euroopa Parlamendi ja nõukogu 20. märtsi 2000. aasta direktiivi 2000/13/EÜ (toidu märgistamist, esitlemist ja reklaami käsitlevate liikmesriikide õigusaktide ühtlustamise kohta) [9] üldpõhimõtteid.
Subsequently, the Commission went back to the Authority to seek further advice to enable the risk managers to set appropriate conditions of use for the relevant health claims.
Pärast seda, kui McNeil Nutritionals ja Raisio Nutrition Ltd olid esitanud määruse (EÜ) nr 1924/2006 artikli 14 lõike 1 punkti a kohase taotluse, pidi toiduohutusamet esitama arvamuse tervisealase väite kohta seoses igapäevaselt 2 g taimsete stanoolide tarbimisega stanoolestrite kujul väikese küllastunud rasvhapete sisaldusega toidu koostises ning vere LDL-kolesterooli taseme kaks korda suurema alanemisega võrreldes üksnes väikese küllastunud rasvhapete sisaldusega toidu tarbimisega (küsimus nr EFSA-Q-2012-00915) [10].
The Authority concluded in its opinion received by the Commission and the Member States on 17 May 2010 (Question No EFSA-Q-2009-00940) [3] that at least 1200 mg of calcium from all sources or at least 1200 mg of calcium and 800 I.U.
„Igapäevaselt 2 g taimsete stanoolide tarbimine stanoolestrite kujul väikese küllastunud rasvhapete sisaldusega toidu koostises vähendab LDL-kolesterooli taset kaks korda rohkem kui üksnes väikese küllastunud rasvhapete sisaldusega toidu tarbimine.
(20 μg) of vitamin D from all sources should be consumed daily in order to obtain the claimed effect.
Kõrge kolesteroolitase on südame isheemiatõve kujunemise riskitegur.”
When the health claim is made only on calcium, in order to ensure that a food provides a significant quantity of calcium, it is appropriate to set conditions of use which allow the claim to be made only on foods which provide at least 400 mg of calcium per quantified portion.
Esitatud andmete alusel jõudis toiduohutusamet 8. aprillil 2013 komisjonile ja liikmesriikidele saadetud arvamuses järeldusele, et taotleja esitatud tõenditest ei nähtu, et igapäevaselt 2 g taimsete stanoolide tarbimine stanoolestrite kujul väikese küllastunud rasvhapete sisaldusega toidu koostises vähendab LDL-kolesterooli taset kaks korda rohkem kui üksnes väikese küllastunud rasvhapete sisaldusega toidu tarbimine.
Taking into account the high level of vitamin D intake required to achieve the claimed effect (20 μg), when the health claim is made on the combination of calcium and vitamin D, it is appropriate to limit the use of the claim to food supplements.
Komisjon on käesoleva määrusega ette nähtud meetmete sätestamisel võtnud arvesse määruse (EÜ) nr 1924/2006 artikli 16 lõike 6 kohaselt taotlejatelt ja üldsuse esindajatelt laekunud märkusi.
In order to ensure that a food supplement would provide a significant quantity of calcium and vitamin D in the context of this claim, it is appropriate to set conditions of use which allow the claim to be made only on food supplements which provide at least 400 mg of calcium and 15 μg of vitamin D per daily portion.
Ainete lisamist toiduainetesse või nende kasutamist toiduainetes ning toodete klassifitseerimist toiduaineteks või ravimiteks reguleeritakse liidu ja riikide eriõigusaktidega.
Following an application from DSM Nutritional Products Europe AG, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of vitamin D and risk of falling for men and women 60 years of age and older (Question No EFSA-Q-2010-01233) [4].
Ükski määruse (EÜ) nr 1924/2006 kohaselt tervisealase väite kohta tehtud otsus, näiteks otsus kõnealuse määruse artikli 14 lõikes 1 osutatud lubatud väidete nimekirja lisamise kohta, ei kujuta endast väites käsitletava aine müügiloa andmist, otsust aine toiduaines kasutamise lubamise kohta ega teatava toote klassifitseerimist toiduaineks.
‘Vitamin D reduces the risk of falling.
Käesoleva määrusega ette nähtud meetmed on kooskõlas toiduahela ja loomatervishoiu alalise komitee arvamusega,
A reduction in the risk of falling among men and women 60 years of age and older is beneficial to human health by reducing the risk of bone fractures.
Käesoleva määruse II lisas loetletud tervisealaseid väiteid ei lisata määruse (EÜ) nr 1924/2006 artikli 14 lõikes 1 osutatud Euroopa Liidu lubatud väidete nimekirja.
Accordingly, a health claim reflecting this conclusion should be considered as complying with the requirements of Regulation (EC) No 1924/2006, and should be included in the Union list of permitted claims.
Käesolev määrus jõustub kahekümnendal päeval pärast selle avaldamist Euroopa Liidu Teatajas.
In its opinion, the Authority also concluded that 800 I.U.
ELT L 404, 30.12.2006, lk 9.
(20 μg) of vitamin D, from all sources, should be consumed daily in order to obtain the claimed effect.
EFSA Journal 2009; 1180: 1–13.
Taking into account the high level of vitamin D intake required to achieve the claimed effect (20 μg), it is appropriate to limit the use of the claim to food supplements.
EFSA Journal 2010; 8(5): 1609.
In order to ensure that a food supplement would provide a significant quantity of vitamin D in the context of this claim, it is appropriate to set conditions of use which allow the claim to be made only on food supplements which provide at least 15 μg of vitamin D per daily portion.
EFSA Journal 2011; 9(9): 2382.
Article 16(4) of Regulation (EC) No 1924/2006 provides that an opinion in favour of authorising a health claim should include certain particulars.
EFSA Journal 2009; 7(10): 1358.
Accordingly, those particulars should be set out in Annex I to this Regulation as regards the authorised claims and include, as the case may be, the revised wording of the claim, specific conditions of use of the claim, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
EFSA Journal 2012; 10(2): 2555.
One of the objectives of Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that wording and presentation are taken into account in that respect.
EFSA Journal 2012; 10(7): 2810.
Therefore where the wording of claims has the same meaning for consumers as that of an authorised health claim, because they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, they should be subject to the same conditions of use indicated in Annex I to this Regulation.
EFSA Journal 2013; 11(4): 3161.
Following an application from GP International Holding B.V., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucosamine hydrochloride and reduced rate of cartilage degeneration (Question No EFSA-Q-2009-00412) [5].
EÜT L 109, 6.5.2000, lk 29.
‘Slowing down/reduce the destruction process of cartilage of the musculoskeletal system and consequently reduce the risk of osteoarthritis’.
EFSA Journal 2013; 11(4): 3160.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 29 October 2009 that a cause and effect relationship had not been established between the consumption of glucosamine hydrochloride and the claimed effect.
I LISA
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Lubatud tervisealased väited
Following an application from the European Natural Soyfood Manufacturers Association (ENSA), the European Vegetable Protein Federation (EUVEPRO) and the Soya Protein Association (SPA), submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of isolated soy protein on reduction of blood LDL-cholesterol concentrations (Question No EFSA-Q-2011-00784) [6].
Taotlus — määruse (EÜ) nr 1924/2006 asjakohased sätted
‘Protein-rich soybean component has been shown to lower/reduce blood cholesterol; blood cholesterol lowering may reduce the risk of (coronary) heart disease’.
Taotleja — aadress
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 2 February 2012 that a cause and effect relationship had not been established between the consumption of isolated soy protein, as defined by the applicant, and the claimed effect.
Toitaine, aine, toit või toidugrupp
Following an application from Health Concern B.V., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-cholesterol concentrations (Question No EFSA-Q-2009-00237, EFSA-Q-2011-01114) [7].
Väide
‘Actively lowers cholesterol’.
Väite kasutamise tingimused
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 17 July 2012 that a cause and effect relationship had not been established between the consumption of a combination of plant sterols and Cholesternorm®mix and the claimed effect at the proposed conditions of use.
Toidu kasutamise tingimused ja/või piirangud ja/või lisaselgitus või hoiatus
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
EFSA arvamuse viide
Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of eicosapentaenoic acid (EPA) on a reduction of the Arachidonic Acid (AA)/EPA ratio in blood in children with attention deficit hyperactivity disorder (ADHD) (Question No EFSA-Q-2012-00573) [8].
Artikli 14 lõike 1 punkti a kohane haigestumise riski vähendamisele osutav tervisealane väide
The claim proposed by the applicant was worded as follows:
Abtei Pharma Vertriebs GmbH, Abtei 1, 37696, Marienműnster, Saksamaa
‘EPA has been shown to reduce the AA/EPA ratio in blood.
Kaltsium
A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms.
Kaltsium aitab vähendada luu mineraalaine kadu menopausijärgses eas naistel.
These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour’.
Luu mineraalaine väike tihedus on osteoporoosist tingitud luumurdude riskitegur.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 8 April 2013 that the target population for the claim is a diseased population (i.e. children with ADHD) and that the claimed effect relates to the treatment of a disease.
Väidet võib kasutada üksnes toidu kohta, mis sisaldab vähemalt 400 mg kaltsiumi kindlaksmääratud suurusega portsjoni kohta.
Regulation (EC) No 1924/2006 complements the general principles of Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs [9].
Tarbijat tuleb teavitada, et väide on konkreetselt suunatud 50-aastastele ja vanematele naistele ning et kasuliku mõju avaldumiseks tuleb igapäevaselt tarbida kõikidest allikatest kokku vähemalt 1200 mg kaltsiumi.
Article 2(1)(b) of Directive 2000/13/EC provides that the labelling shall not attribute to any foodstuff the property of preventing, treating or curing a human disease, or refer to such properties.
Kaltsiumilisandiga toitude puhul võib väidet kasutada üksnes nende toitude kohta, mille sihtrühm on 50-aastased ja vanemad naised
Accordingly, as the attribution of medicinal properties to foods is prohibited, the claim related to the effects of eicosapentaenoic acid (EPA) on a reduction of the AA/EPA ratio in blood in children with ADHD should not be authorised.
Kaltsium ja D-vitamiin
Following an application from McNeil Nutritionals and Raisio Nutrition Ltd, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of 2 g/day of plant stanols (as plant stanol esters) as part of a diet low in saturated fat and a two-fold greater reduction in blood LDL-cholesterol concentrations compared to the consumption of a diet low in saturated fat alone (Question No EFSA-Q-2012-00915) [10].
Kaltsium ja D-vitamiin aitavad vähendada luu mineraalaine kadu menopausijärgses eas naistel.
‘Consuming 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a 2-fold greater reduction in LDL-cholesterol than consuming a low saturated fat diet alone.
Väidet võib kasutada üksnes toidulisandite kohta, mis sisaldavad vähemalt 400 mg kaltsiumi ja 15 μg D-vitamiini päevase portsjoni kohta.
High cholesterol is a risk factor in the development of coronary heart disease’.
Tarbijat tuleb teavitada, et väide on konkreetselt suunatud 50-aastastele ja vanematele naistele ning et kasuliku mõju avaldumiseks tuleb igapäevaselt tarbida kõikidest allikatest kokku vähemalt 1200 mg kaltsiumi ja 20 μg D-vitamiini.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 8 April 2013 that the evidence provided by the applicant does not establish that the consumption of 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a two-fold greater reduction in LDL-cholesterol concentrations compared with consuming a diet low in saturated fat alone.
Kaltsiumilisandiga ja D-vitamiini lisandiga toitude puhul võib väidet kasutada üksnes nende toitude kohta, mille sihtrühm on 50-aastased ja vanemad naised
The comments from the applicants and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
Box 2676, 4002 Basel, Šveits
The addition of substances to or the use of substances in foodstuffs is governed by specific Union and national legislation, as is the classification of products as foodstuffs or medicinal products.
D-vitamiin
Any decision on a health claim in accordance with Regulation (EC) No 1924/2006 such as inclusion in the list of permitted claims referred to in Article 14(1) thereof does not constitute an authorisation to the marketing of the substance on which the claim is made, a decision on whether the substance can be used in foodstuffs, or a classification of a certain product as a foodstuff.
D-vitamiin aitab vähendada kehahoiaku ebastabiilsuse ja lihasnõrkusega seotud kukkumisohtu.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,
Kukkumine on 60-aastaste ja vanemate meeste ja naiste luumurdude riskitegur.
The health claims listed in Annex I to this Regulation may be made on foods placed on the Union market in compliance with the conditions laid down in that Annex.
Väidet võib kasutada üksnes toidulisandite kohta, mis sisaldavad vähemalt 15 μg D-vitamiini päevase portsjoni kohta.
The health claims referred to in paragraph 1 shall be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Tarbijat tuleb teavitada, et kasuliku mõju avaldumiseks tuleb igapäevaselt tarbida kõikidest allikatest kokku 20 μg D-vitamiini.
The health claims listed in Annex II to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
D-vitamiini lisandiga toidulisandite puhul võib väidet kasutada üksnes nende toidulisandite kohta, mille sihtrühm on 60-aastased ja vanemad mehed ja naised
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
II LISA
OJ L 404, 30.12.2006, p. 9.
Tagasi lükatud tervisealased väited
EFSA Journal (2009) 1180, 1-13.
Glükoosamiinvesinikkloriid
EFSA Journal (2010);8(5):1609.
Aeglustab skeleti-lihassüsteemi kõhre lagunemisprotsessi ja vähendab sellega osteoartriidi riski
EFSA Journal (2011);9(9):2382.
Eraldatud sojavalk
EFSA Journal 2009;7(10):1358.
On tõendatud, et sojaoa valgurikas komponent alandab vere kolesteroolitaset, mis võib omakorda vähendada südamehaiguste, sealhulgas südame isheemiatõve riski
EFSA Journal 2012;10(2):2555.
Taimsete steroolide ja toote Cholesternorm®mix kombinatsioon
EFSA Journal 2012;10(7):2810.
Alandab aktiivselt kolesteroolitaset
EFSA Journal 2013;11(4):3161.
Eikosapentaeenhape
OJ L 109, 6.5.2000, p. 29.
On tõendatud, et eikosapentaeenhape vähendab arahhidoonhappe ja eikosapentaeenhappe suhtarvu veres.
EFSA Journal 2013;11(4):3160.
Suur arahhidoonhappe ja eikosapentaeenhappe suhtarv on tähelepanuraskuste tekkimise riskitegur tähelepanupuudulikkuse ja hüperaktiivsuse sündroomi meenutavate sümptomitega lastel.
ANNEX I
Sellistele lastele on iseloomulik ka väiksem hüperaktiivsus ja/või samaaegselt esinev tõrksus käitumises.
Permitted health claims
Taimsed stanoolid stanoolestrite kujul
Application — Relevant provisions of Regulation (EC) No 1924/2006
Igapäevaselt 2 g taimsete stanoolide tarbimine stanoolestrite kujul väikese küllastunud rasvhapete sisaldusega toidu koostises vähendab LDL-kolesterooli taset kaks korda rohkem kui üksnes väikese küllastunud rasvhapete sisaldusega toidu tarbimine.
Applicant — Address
Kõrge kolesteroolitase on südame isheemiatõve kujunemise riskitegur.
Nutrient, substance, food or food category
Toiduohutusamet jõudis 17. mail 2010 komisjonile ja liikmesriikidele saadetud arvamuses (küsimus nr EFSA-Q-2009-00940) [3] järeldusele, et väidetava mõju saavutamiseks tuleks igapäevaselt tarbida kõikidest allikatest kokku vähemalt 1200 mg kaltsiumi või vähemalt 1200 mg kaltsiumi ja 800 RÜ (20 μg) D-vitamiini.
Claim
Samuti jõudis toiduohutusamet oma arvamuses järeldusele, et väidetava mõju saavutamiseks tuleks igapäevaselt tarbida kõikidest allikatest kokku 800 RÜ (20 μg) D-vitamiini.
Conditions of use of the claim
Q-2009-00940
Commission Regulation (EU) No 1229/2014
Komisjoni määrus (EL) nr 1229/2014,
Following an application from Italsur S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of Tuscan black cabbage, ‘tri-coloured’ Swiss chard, ‘bi-coloured’ spinach and ‘blu savoy’ cabbage and protection of blood lipids from oxidative damage (Question No EFSA-Q-2013-00574) [2].
Pärast seda, kui Italsur s.r.l. oli esitanud määruse (EÜ) nr 1924/2006 artikli 13 lõike 5 kohase taotluse, pidi toiduohutusamet esitama arvamuse tervisealase väite kohta seoses lehtkapsa „Nero di Toscana”, kolmevärvilise lehtpeedi, kahevärvilise spinati ja sinise kähara peakapsa kombinatsiooni mõjuga ning vere lipiidide kaitsega oksüdatiivse kahjustuse eest (küsimus nr EFSA-Q-2013-00574) [2].